XOMA (XOMAO) Stock Price, News & Analysis

Company Overview

XOMA Corporation is a biotechnology royalty aggregator that acquires economic interests in potential future payments from partnered pharmaceutical and biotechnology programs. Rather than operating primarily as a traditional drug developer, the company builds a portfolio of rights to milestone payments, royalties and other commercial proceeds associated with therapeutic candidates and marketed medicines.

The company’s portfolio has included programs across areas such as immunology, oncology, rare diseases and infectious diseases. XOMA typically obtains these interests through licensing transactions, acquisitions or partnerships involving biotechnology companies and other life sciences organizations. The value of its business is tied to the clinical development, regulatory progress and commercial performance of the underlying programs owned or advanced by its partners.

Founded in 1981, XOMA historically focused on discovering and developing antibody-based therapeutics before transitioning toward its current royalty-aggregation model. The company is headquartered in Emeryville, California, and works with biotechnology and pharmaceutical partners internationally. XOMAO represents XOMA’s Series A preferred stock, while the company’s common stock trades under the symbol XOMA.

Key Stats

• Today's Range: $25.00 to $25.00
• 50-Day Range: $25.00 to $25.00
• 52-Week Range: $24.86 to $26.40
• Volume: N/A
• Average Volume: 4,279 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: 8.36%
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Record date for 7/14 Dividend: 7/02/2026
• Ex-Dividend for 7/14 Dividend: 7/02/2026
• Dividend Payable: 7/14/2026
• Today: 9/27/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XOMAO
• CIK: 791908
• Web: www.xoma.com
• Phone: 510-204-7200
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $7.65 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A